Skip to content

Study · Non-randomized trial · n = 22 · 1998

8 results

Desmopressin in the treatment of daytime urinary frequency in patients with multiple sclerosis.

Hoverd PA, Fowler CJ

Journal of neurology, neurosurgery, and psychiatry1 Nov 1998Cited by 32 (Europe PMC)

PMID9810957 (opens in a new tab)PMCIDPMC2170321 (opens in a new tab)DOI10.1136/jnnp.65.5.778 (opens in a new tab)PepBankPUB-09810957
Source linkPubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with multiple sclerosis, desmopressin reduced voids over 6 hours to 2.4 versus 3.1 after placebo.

    In plain wordsIn patients with multiple sclerosis, desmopressin reduced urination frequency compared with placebo.

    Peptide
    Desmopressin
    Outcome
    DecreaseMicturition frequency
    Study

    n = 22

    Comparator
    Placebo
    Outcome group
    Urinary function · Kidney and urinary
    Studied dose
    Dose not stated · nasal sprayAs given in this study (human).

    Measurements

    Micturition frequency in 6 hour post-treatment period
    2.4 voids
    after desmopressin
    Micturition frequency in 6 hour post-treatment period
    3.1 voids
    after placebo

    Source sentences

    Summary
    There was a significant decrease in micturition frequency in the 6 hour post-treatment period from 3.1 voids after placebo to 2.4 voids and a significant reduction in urinary volume after desmopressin.
    1 context sentence
    Summary · context
    Twenty two patients with multiple sclerosis, complaining of frequency of day time micturition, completed a double blind crossover trial of desmopressin (DDAVP nasal spray) versus placebo.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with multiple sclerosis, desmopressin significantly reduced urinary volume versus placebo.

    In plain wordsIn patients with multiple sclerosis, desmopressin reduced urine volume compared with placebo.

    Peptide
    Desmopressin
    Outcome
    DecreaseUrinary volume
    Study

    n = 22

    Comparator
    Placebo
    Outcome group
    Urinary function · Kidney and urinary
    Studied dose
    Dose not stated · nasal sprayAs given in this study (human).

    Source sentences

    Summary
    There was a significant decrease in micturition frequency in the 6 hour post-treatment period from 3.1 voids after placebo to 2.4 voids and a significant reduction in urinary volume after desmopressin.
    1 context sentence
    Summary · context
    Twenty two patients with multiple sclerosis, complaining of frequency of day time micturition, completed a double blind crossover trial of desmopressin (DDAVP nasal spray) versus placebo.
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with multiple sclerosis, eighty per cent preferred the desmopressin phase.

    In plain wordsIn patients with multiple sclerosis, eighty per cent preferred desmopressin to placebo.

    Peptide
    Desmopressin
    Outcome
    Not applicableTreatment preference
    Study

    n = 22

    Comparator
    Placebo
    Outcome group
    Patient-reported outcomes · Kidney and urinary
    Studied dose
    Dose not stated · nasal sprayAs given in this study (human).

    Measurements

    Patients preferring the active treatment phase
    80%
    double-blind crossover, desmopressin versus placebo

    Source sentences

    Summary
    Eighty per cent of patients preferred the active treatment phase.
    1 context sentence
    Summary · context
    Twenty two patients with multiple sclerosis, complaining of frequency of day time micturition, completed a double blind crossover trial of desmopressin (DDAVP nasal spray) versus placebo.
  4. 04HumanNon-randomized trialEfficacy outcome

    In patients with multiple sclerosis, mean 24 hour urine volume did not differ between desmopressin and placebo.

    In plain wordsIn patients with multiple sclerosis, daily urine volume did not differ between desmopressin and placebo.

    Peptide
    Desmopressin
    Outcome
    No significant change24 hour urinary volume
    Study

    n = 22

    Comparator
    Placebo
    Outcome group
    Urinary function · Kidney and urinary
    Studied dose
    Dose not stated · nasal sprayAs given in this study (human).

    Source sentences

    Summary
    Mean 24 hour urinary volume did not differ between active and placebo treatments and patients did not complain of increased night time frequency.
    1 context sentence
    Summary · context
    Twenty two patients with multiple sclerosis, complaining of frequency of day time micturition, completed a double blind crossover trial of desmopressin (DDAVP nasal spray) versus placebo.
  5. 05HumanNon-randomized trialSafety outcome

    Patients with multiple sclerosis did not complain of increased night-time frequency during the desmopressin trial.

    In plain wordsPatients with multiple sclerosis did not report increased night-time urination during the desmopressin trial.

    Peptide
    Desmopressin
    Outcome
    Not applicableIncreased night-time frequency complaints
    Study

    n = 22

    Outcome group
    Adverse events · Kidney and urinary
    Studied dose
    Dose not stated · nasal sprayAs given in this study (human).

    Source sentences

    Summary
    Mean 24 hour urinary volume did not differ between active and placebo treatments and patients did not complain of increased night time frequency.
    1 context sentence
    Summary · context
    Twenty two patients with multiple sclerosis, complaining of frequency of day time micturition, completed a double blind crossover trial of desmopressin (DDAVP nasal spray) versus placebo.
  6. 06HumanNon-randomized trialSafety outcome

    One patient had transient hyponatraemia symptoms that resolved within 48 hours after desmopressin stopped.

    In plain wordsOne patient had low-sodium symptoms that resolved within 48 hours after desmopressin stopped.

    Peptide
    Desmopressin
    Outcome
    Not applicableTransient hyponatraemia symptoms
    Study

    n = 22

    Outcome group
    Adverse events · Kidney and urinary
    Studied dose
    Dose not stated · nasal sprayAs given in this study (human).

    Measurements

    Patients with transient hyponatraemia symptoms
    1 patients
    desmopressin crossover trial
    Time to resolution after stopping desmopressin
    ≤ 48 hours
    hyponatraemia symptoms resolved within

    Source sentences

    Summary
    Transient symptoms of hyponatraemia occurred in one patient but these resolved within 48 hours of stopping desmopressin.
    1 context sentence
    Summary · context
    Twenty two patients with multiple sclerosis, complaining of frequency of day time micturition, completed a double blind crossover trial of desmopressin (DDAVP nasal spray) versus placebo.
  7. 07HumanNon-randomized trialSafety outcome

    In the multiple sclerosis trial, no other side effects occurred with desmopressin.

    In plain wordsIn the multiple sclerosis trial, no other side effects occurred with desmopressin.

    Peptide
    Desmopressin
    Outcome
    Not applicableOther side effects
    Study

    n = 22

    Outcome group
    Adverse events · Kidney and urinary
    Studied dose
    Dose not stated · nasal sprayAs given in this study (human).

    Source sentences

    Summary
    There were otherwise no side effects and mean serum sodium concentrations of the group remained unchanged throughout the study.
    1 context sentence
    Summary · context
    Twenty two patients with multiple sclerosis, complaining of frequency of day time micturition, completed a double blind crossover trial of desmopressin (DDAVP nasal spray) versus placebo.
  8. 08HumanNon-randomized trialSafety outcome

    In the multiple sclerosis trial, mean serum sodium remained unchanged throughout treatment.

    In plain wordsIn the desmopressin trial, average blood sodium remained unchanged.

    Peptide
    Desmopressin
    Outcome
    No significant changeMean serum sodium
    Study

    n = 22

    Outcome group
    Adverse events · Kidney and urinary
    Studied dose
    Dose not stated · nasal sprayAs given in this study (human).

    Source sentences

    Summary
    There were otherwise no side effects and mean serum sodium concentrations of the group remained unchanged throughout the study.
    1 context sentence
    Summary · context
    Twenty two patients with multiple sclerosis, complaining of frequency of day time micturition, completed a double blind crossover trial of desmopressin (DDAVP nasal spray) versus placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.